Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

David Moreno to Female

This is a "connection" page, showing publications David Moreno has written about Female.

 
Connection Strength
 
 
 
0.099
 
  1. Moreno DF, Oriol A, de la Rubia J, Hern?ndez MT, I?igo MB, Palomera L, de Arriba F, Gonz?lez Y, Teruel AI, Pardo JL, L?pez de la Gu?a A, Sampol A, R?os-Tamayo R, Sureda A, Guti?rrez NC, Calasanz MJ, Ramos MLM, Mateos MV, San Miguel J, Lahuerta JJ, Blad? J, Rosi?ol L. Is t(11;14) Always a Standard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA/GEM Transplantation Trials. Clin Lymphoma Myeloma Leuk. 2025 Jul; 25(7):494-504.
    View in: PubMed
    Score: 0.035
  2. Rodr?guez-Lobato LG, de Daniel A, Pereira A, Fern?ndez de Larrea C, Tovar N, Cibeira MT, Moreno DF, Mateos JM, Llobet N, Carcelero E, Mun?rriz D, Blad? J, Rosi?ol L. Attrition rates and treatment outcomes in multiple myeloma: real-world data over a 40-year period. Blood Cancer J. 2025 May 26; 15(1):103.
    View in: PubMed
    Score: 0.009
  3. Zugasti I, Tormo-Ratera M, Oliver-Cald?s A, Soler-Perromat JC, Gonz?lez-Calle V, Moreno DF, Caba?as V, L?pez-Mu?oz N, Bartolom?-Solanas ?, Espa?ol-Rego M, Reguera-Ortega JL, Rosi?ol L, L?pez-Corral L, Tovar N, Rodr?guez-Lobato LG, Alvarez Perez RM, Varea S, Olesti E, Gomez-Grande A, Frutos L, Tamayo P, Juan M, Moraleda JM, Urbano-Ispizua ?, Gonz?lez-Navarro EA, Mart?nez-L?pez J, Mateos MV, Tom?s X, Setoain X, Fern?ndez de Larrea C. Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myeloma. Blood Adv. 2025 Feb 11; 9(3):571-582.
    View in: PubMed
    Score: 0.009
  4. Oliver-Caldes A, Espa?ol-Rego M, Zabaleta A, Gonz?lez-Calle V, Navarro-Vel?zquez S, Inog?s S, de Cerio AL, Caba?as V, L?pez-Mu?oz N, Rodr?guez-Otero P, Reguera JL, Moreno DF, Mart?nez-Cibrian N, L?pez-Corral L, P?rez-Amill L, Martin-Antonio B, Rosi?ol L, Cid J, Tovar N, S?ez-Pe?ataro J, L?pez-Parra M, Olesti E, Guill?n E, Varea S, Rodr?guez-Lobato LG, Battram AM, Gonz?lez MS, S?nchez-Salinas A, Gonz?lez-Navarro A, Ortiz-Maldonado V, Delgado J, Pr?sper F, Juan M, Mart?nez-L?pez J, Moraleda JM, Mateos MV, Urbano-Ispizua ?, Paiva B, Pascal M, Fern?ndez de Larrea C. Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma. Clin Cancer Res. 2024 May 15; 30(10):2085-2096.
    View in: PubMed
    Score: 0.008
  5. Oliver-Caldes A, Jim?nez R, Espa?ol-Rego M, Cibeira MT, Ortiz-Maldonado V, Quintana LF, Castillo P, Guijarro F, Tovar N, Montoro M, Benitez-Ribas D, Bataller A, Gonz?lez-Navarro EA, Cid J, Lozano M, Perez-Amill L, Martin-Antonio B, Mena MP, Moreno DF, Rodr?guez-Lobato LG, Campistol JM, Calvo G, Blad? J, Rosi?ol L, Juan M, Pascal M, Urbano-Ispizua A, Fern?ndez de Larrea C. First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myeloma. J Immunother Cancer. 2021 12; 9(12).
    View in: PubMed
    Score: 0.007
  6. Isola I, Bras?-Maristany F, Moreno DF, Mena MP, Oliver-Calders A, Par? L, Rodr?guez-Lobato LG, Martin-Antonio B, Cibeira MT, Blad? J, Rosi?ol L, Prat A, Lozano E, Fern?ndez de Larrea C. Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease. Front Immunol. 2021; 12:792609.
    View in: PubMed
    Score: 0.007
  7. Rodr?guez-Lobato LG, Pereira A, Fern?ndez de Larrea C, Cibeira MT, Tovar N, Jim?nez-Segura R, Moreno DF, Oliver-Cald?s A, Rosi?ol L, Blad? J. Real-world data on survival improvement in patients with multiple myeloma treated at a single institution over a 45-year period. Br J Haematol. 2022 02; 196(3):649-659.
    View in: PubMed
    Score: 0.007
  8. Isola I, Moreno DF, Moga E, Mena MP, Tovar N, Rodr?guez-Lobato LG, Oliver-Cald?s A, Salgado MC, Bras?-Maristany F, Yag?e J, Cibeira MT, Prat A, Rosi?ol L, Blad? J, Fern?ndez de Larrea C. Immunoparesis defined by heavy/light chain pair suppression in smoldering multiple myeloma shows initial isotype specificity and involves other isotypes in advanced disease. Ann Hematol. 2021 Dec; 100(12):2997-3005.
    View in: PubMed
    Score: 0.007
  9. Cid J, Carbass? G, Su?rez-Lled? M, Moreno DF, Mart?nez C, Guti?rrez-Garc?a G, Fern?ndez-Avil?s F, Rosi?ol L, Giavedoni P, Mascar? JM, Agust? C, Mar?n P, Rovira M, Urbano-Ispizua ?, Lozano M. Efficacy and safety of one-day offline extracorporeal photopheresis schedule processing one total blood volume for treating patients with graft-versus-host disease. Transfusion. 2019 08; 59(8):2636-2642.
    View in: PubMed
    Score: 0.006
  10. Tagarro A, Otheo E, Baquero-Artigao F, Navarro ML, Velasco R, Ruiz M, Pen?n M, Moreno D, Rojo P, Madero R. Dexamethasone for Parapneumonic Pleural Effusion: A Randomized, Double-Blind, Clinical Trial. J Pediatr. 2017 06; 185:117-123.e6.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)